2024-03-21 04:43:11 ET
Summary
- Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business.
- The company has struggled with acquisitions but is expected to generate strong shareholder returns.
- Gilead Sciences has new businesses and milestones planned for 2024.
Gilead Sciences ( GILD ) has been perhaps one of the most discussed biotech companies as an investment. The company effectively was the first to cure Hepatitis C, capitalizing on an incredibly strong HIV business, before competition hurt its market position substantially....
Read the full article on Seeking Alpha
For further details see:
Gilead Sciences Finally Starts Succeeding